These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35967191)

  • 1. Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey.
    Kondili LA; Buti M; Riveiro-Barciela M; Maticic M; Negro F; Berg T; Craxì A
    JHEP Rep; 2022 Sep; 4(9):100531. PubMed ID: 35967191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Coronavirus Disease 2019 Pandemic on Viral Hepatitis Elimination: What Is the Price?
    Sowah L; Chiou C
    AIDS Res Hum Retroviruses; 2021 Aug; 37(8):585-588. PubMed ID: 33913731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the first, second and third waves of covid-19 on hepatitis B and C testing in Ontario, Canada.
    Mandel E; Peci A; Cronin K; Capraru CI; Shah H; Janssen HLA; Tran V; Biondi MJ; Feld JJ
    J Viral Hepat; 2022 Mar; 29(3):205-208. PubMed ID: 34820967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements.
    Kondili LA; Craxì A; Aghemo A
    Liver Int; 2021 Apr; 41(4):649-655. PubMed ID: 33486885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The case for simplifying and using absolute targets for viral hepatitis elimination goals.
    Polaris Observatory Collaborators
    J Viral Hepat; 2021 Jan; 28(1):12-19. PubMed ID: 32979881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B Gene Therapy Coming to Age.
    Soriano V
    AIDS Rev; 2018; 20(2):125-127. PubMed ID: 29938706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress on global hepatitis elimination targets.
    Waheed Y
    World J Gastroenterol; 2021 Dec; 27(47):8199-8200. PubMed ID: 35068864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of viral hepatitis in solid organ transplantation].
    Mikolašević I; Sladoje-Martinović B; Orlić L; Milić S; Lukenda V; Župan Ž; Štimac D; Rački S
    Acta Med Croatica; 2014 Apr; 68(2):151-9. PubMed ID: 26012153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Securing wider EU commitment to the elimination of hepatitis C virus.
    Wedemeyer H; Tergast TL; Lazarus JV; Razavi H; Bakoyannis K; Baptista-Leite R; Bartoli M; Bruggmann P; Buşoi CS; Buti M; Carballo M; Castera L; Colombo M; Coutinho RS; Dadon Y; Esmat G; Esteban R; Farran JC; Gillyon-Powell M; Goldberg D; Hutchinson S; Janssen HLA; Kalamitsis G; Kondili LA; Lambert JS; Marinho RT; Maticic M; Patricello A; Peck-Radosavljevic M; Pol S; Poljak M; Pop C; Sokol T; Sypsa V; Tözün N; Younossi Z; Aghemo A; Papatheodoridis GV; Hatzakis A
    Liver Int; 2023 Feb; 43(2):276-291. PubMed ID: 36196744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.
    Lazarus JV; Stumo SR; Harris M; Hendrickx G; Hetherington KL; Maticic M; Jauffret-Roustide M; Tallada J; Simojoki K; Reic T; Safreed-Harmon K;
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25052. PubMed ID: 29633562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
    Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
    Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
    Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of COVID-19 on hepatitis B and C virus countermeasures: Hepatologist responses from nationwide survey in Japan.
    Hussain MRA; Hiebert L; Sugiyama A; Ouoba S; Bunthen E; Ko K; Akita T; Kaneko S; Kanto T; Ward JW; Tanaka J
    Hepatol Res; 2022 Nov; 52(11):899-907. PubMed ID: 35861597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS).
    Russo FP; Izzy M; Rammohan A; Kirchner VA; Di Maira T; Belli LS; Berg T; Berenguer MC; Polak WG
    J Hepatol; 2022 Feb; 76(2):364-370. PubMed ID: 34653592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of hepatitis B and C viruses in moderate and severe COVID-19 inpatients: A cross-sectional study at a referral center in Mexico.
    Jiménez-Mendoza JC; Rivera-López FE; González-Lara MF; Valdez-Echeverría RD; Castro-Narro GE; Tore A; Uscanga-Domínguez LF; Moctezuma-Velázquez C
    Ann Hepatol; 2022; 27(3):100684. PubMed ID: 35167956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telemonitoring of the Continuum of Care of Hepatitis C During the COVID-19 Pandemic in Brazil.
    Bittencourt PL; Codes L; César AMDG; Mussi FC; Ferraz MLG
    Telemed J E Health; 2023 Nov; 29(11):1673-1678. PubMed ID: 36888957
    [No Abstract]   [Full Text] [Related]  

  • 20. Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.
    Dunn R; Musabaev E; Razavi H; Sadirova S; Bakieva S; Razavi-Shearer K; Brigida K; Kamili S; Averhoff F; Nasrullah M
    MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(34):1161-1165. PubMed ID: 32853186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.